Big reactions in stocks based on earnings results and tariff uncertainty underscore an "internal battle" playing out in U.S stocks right now, said Keith Lerner, co-chief investment officer at Truist ...

Eli Lilly is getting closer to bringing a weight loss pill to market, but CEO David Ricks notes certain factors need to be considered to prevent prices from ballooning.

He is an experienced journalist who has covered everything from the latest in business and tech news to sports and international news like the war in Ukraine ... Shares of Eli Lilly jumped 16% ...

Eli Lilly, for its part, sells tirzepatide as Mounjaro and Zepbound for diabetes and obesity, respectively. In addition, retatrutide is Lilly’s next-generation weight loss candidate.